Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Magnera Corporation

MAGN
Consumer Staples · Household & Personal Products

Magnera Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is between stages. Underneath, the last four quarters read mixed, and 660% of the last 2 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Price
$11.6
+4.3% 1Y
Revenue (Mar 26)
$0.8 B
−2.4% YoY
Profit (Mar 26)
$−0.0 B
Operating margin
2.5%
+2.5 pp YoY
ROE
−10%
FY25
ROIC
5.3%
Cash conversion
660%
of profit, last 2 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Magnera Corporation trades at $11.6, between stages. That is −6.2% against its own 200-day average. It sits at 46% of a 52-week range of $9 to $15. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (2 weeks and counting).

Today the stock is between stages. At $11.6 it trades −6.2% versus its 200-day average and sits at 46% of its 52-week range ($9–$15).

Sep 26: $11.6 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
−6.2% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$15.6$13.8$11.9$10.1$8.2$$12$12Jul 25Oct 25Feb 26May 26Sep 26
$15.6$13.8$11.9$10.1$8.2$$12$12Jul 25Feb 26Sep 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (63 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Sep 26

Against the market, two honest reads. Cumulative: over the last 1.2 years the stock moved −12% while the S&P 500 moved +21% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price Magnera Corporation — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Magnera Corporation reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +46.1% in FY25 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
57%−298.8%41%−299.4%24%−300.0%8.2%−300.6%−8.0%−301.2%%%46.1%−300%FY21FY23FY25
57%−298.8%41%−299.4%24%−300.0%8.2%−300.6%−8.0%−301.2%%%46.1%−300%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising
RevenueProfitEPS
67%−192%49%−221%31%−250%13%−279%−5.0%−308%%%35.7%−200%−300%Jun 23Sep 24Mar 26
67%−192%49%−221%31%−250%13%−279%−5.0%−308%%%35.7%−200%−300%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
2.5%1.7%0.9%0.2%−0.6%%1.5%Jun 23Dec 23Sep 24Jun 25Mar 26
2.5%1.7%0.9%0.2%−0.6%%1.5%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +35.7% · span +0.0% to +62.4%
ROCE
Stuck low
latest 1.5% · span −0.4%–2.3%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+46.1%+29.0%
Stock price+4.3%
Revenue YoY (Mar 26)
−2.4%
latest quarter vs a year ago
Revenue 10y
31.2%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

43.7/100 — rank 10 of 20 in Household & Personal Products · 58% evidence confidence

Magnera Corporation scores 43.7 out of 100 against the 20 companies it is compared with in Household & Personal Products, ranking 10. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 21.4 + 5.7 + 11.2 + 5.4 = 43.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Magnera Corporation reported $0.8 B of revenue in the Mar 26 quarter, −2.4% year on year. Over 4 years it has compounded at 31.2% a year. The last full year, FY25, came in at $3.2 B. The last four reported quarters add to $3.3 B.

FY25 revenue came in at $3.2 B (+46.1% on the year), capping 4 years at 31.2% compound. The latest quarter (Mar 26) printed $0.8 B, −2.4% year on year.

FY25 revenue $3.2 B (+46.1% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
31.2% a year over 4 years
RevenueYoY growth
3.557%2.641%1.724%0.98.2%0.0−8.0%$ B%$3B46.1%FY21FY23FY25
3.557%2.641%1.724%0.98.2%0.0−8.0%$ B%$3B46.1%FY21FY23FY25
Mar 26: $0.8 B (−2.4% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.9168%0.7120%0.572%0.224%0.0−24%$ B%$1B−2.4%Jun 23Sep 24Mar 26
0.9168%0.7120%0.572%0.224%0.0−24%$ B%$1B−2.4%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +53.8% growth against the decade's 31.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +35.7% over the last 4 quarters against +35.9%/yr over the last 8 — stabilising.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Magnera Corporation's operating margin is 2.5% in the Mar 26 quarter, +2.5 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −10.7% to 3.1%. The current quarter sits inside that band.

The latest quarter's operating margin is 2.5%, +2.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −10.7%–3.1%.

Why the margin moved: operating margin went +2.5 pp year on year while gross margin went +1.5 pp — the gain came mostly from the gross line: input costs and pricing.

FY25: 0.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −10.7–3.1% band over 5 years
operating marginYoY change (pp)
4.2%16%0.2%8.1%−3.8%0.0%−7.8%−7.8%−12%−16%%%0.3%6.7%FY21FY23FY25
4.2%16%0.2%8.1%−3.8%0.0%−7.8%−7.8%−12%−16%%%0.3%6.7%FY21FY23FY25
Mar 26: 2.5% operating margin (+2.5 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
4.1%9.2%2.2%5.2%0.4%1.3%−1.5%−2.7%−3.4%−6.7%%%2.5%2.5%Jun 23Sep 24Mar 26
4.1%9.2%2.2%5.2%0.4%1.3%−1.5%−2.7%−3.4%−6.7%%%2.5%2.5%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Magnera Corporation posted a net loss of $0.02 B in the Mar 26 quarter. The full FY25 year was a loss of $0.2 B. That loss is 2.5% of the quarter's revenue. The same quarter a year earlier lost $0.04 B. 10 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.2 B (null).

FY25 profit $−0.2 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.06−353%−0.01−795%−0.07−1,238%−0.14−1,680%−0.21−2,122%$ B%$−0B−475%FY21FY23FY25
0.06−353%−0.01−795%−0.07−1,238%−0.14−1,680%−0.21−2,122%$ B%$−0B−475%FY21FY23FY25
Mar 26: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.03−176%0.00−263%−0.02−350%−0.04−437%−0.07−524%$ B%$0B−200%Jun 23Sep 24Mar 26
0.03−176%0.00−263%−0.02−350%−0.04−437%−0.07−524%$ B%$0B−200%Jun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years 660% of Magnera Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $−0.2 B of profit. After $0.1 B of capital spending, $0.0 B was left as free cash.

FY25: operating cash of $0.1 B against reported profit of $−0.2 B, leaving free cash of $0.0 B after $0.1 B of capital spending. Across the last 2 fiscal years the conversion rate is 660% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.1 B vs profit $−0.2 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
660% of 2-year profit arrived as cash
Operating cashNet profitFree cash
0.30.20.0−0.1−0.2$ B$0B$−0B$0BFY21FY23FY25
0.30.20.0−0.1−0.2$ B$0B$−0B$0BFY21FY23FY25
Mar 26: operating cash $0.1 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.11564%0.07332%0.02100%−0.03−132%−0.07−364%$ B%$0B500%Mar 23Sep 24Mar 26
0.11564%0.07332%0.02100%−0.03−132%−0.07−364%$ B%$0B500%Mar 23Sep 24Mar 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Magnera Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.1 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.100.070.050.020.00$ B$0BFY21FY23FY25
0.100.070.050.020.00$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0220.090.0160.050.0110.010.005−0.040.000−0.08$ B$ B$0B$0BMar 23Sep 24Mar 26
0.0220.090.0160.050.0110.010.005−0.040.000−0.08$ B$ B$0B$0BMar 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Magnera Corporation earns a ROE of −15% in FY25. That is up from a trough of −59% in FY22. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −5.0% net margin on 0.80× asset turns.

FY25 ROE is −15%, recovered from a FY22 trough of −59% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): −5.0% net margin × 0.80× asset turns × 3.76× balance-sheet leverage ≈ −15.0% on equity. Margin does its share; leverage is a meaningful part of the equation.

FY25: ROE −15% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included.
the climb back from FY22's −59%
ROEROIC (annual)
22%0.0%−22%−44%−65%%−15.1%0.2%FY21FY23FY25
22%0.0%−22%−44%−65%%−15.1%0.2%FY21FY23FY25
Mar 26: ROIC 0.7% (TTM) Trailing-twelve-month ROIC and ROE, per quarter, %. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)
20%4.8%−10%−25%−41%%0.7%−9.7%Jun 23Sep 24Mar 26
20%4.8%−10%−25%−41%%0.7%−9.7%Jun 23Sep 24Mar 26
11 · Dividend

Dividend

Magnera Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Magnera Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Magnera Corporation carries total debt of $1.9 B against shareholder equity of $1.0 B as of Mar 26, a debt-to-equity of 1.87. On the annual view that ratio went from 1.46 in FY21 to 1.89 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $1.9 B against shareholder equity of $1.0 B — a debt-to-equity of 1.87. On the annual view, debt-to-equity went from 1.46 (FY21) to 1.89 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $2.0 B at 1.89× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
2.23.7×1.62.7×1.11.8×0.50.8×0.0−0.2×$ B×$2B1.89×FY21FY23FY25
2.23.7×1.62.7×1.11.8×0.50.8×0.0−0.2×$ B×$2B1.89×FY21FY23FY25
Mar 26: debt $1.9 B, debt-to-equity 1.87 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
2.24.5×1.73.3×1.12.1×0.60.9×0.0−0.3×$ B×$2B1.87×Jun 23Sep 24Mar 26
2.24.5×1.73.3×1.12.1×0.60.9×0.0−0.3×$ B×$2B1.87×Jun 23Sep 24Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

6.5% of Magnera Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 6.5% of the float is sold short, and at typical trading volumes it would take about 4.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
6.5%
of the tradable float
Days to cover
4.0
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Magnera Corporation: the Z-score reads 1.24. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

🚨 Why it matters: a Z-score of 1.24 is inside the distress zone — the balance sheet is a real risk, not a detail.

The safety line in one sentence: the Z-score reads 1.24.

15 · Related companies · Household & Personal Products
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Helen of Troy LimitedHELE 67.7/100Favorable setup71% evidence FADING 23.9/35 Revenue -2.5% · PAT 100% · OPM change 124.5 pp 71% evidence 12.4/25 ROCE 3.2% · OPM 15% 76% evidence 16.3/20 P/E 10.2× · PEG 0.42 65% evidence 15.1/20 RS sector 13.5% · RS bench 14.9% · 1Y 20.3%9 of 12 weeks ahead 70% evidence
Exact sum: 23.9 + 12.4 + 16.3 + 15.1 = 67.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Interparfums, Inc.IPAR 56.9/100Mixed-positive evidence81% evidence BREAKING OUT 15.5/35 Revenue 1.8% · PAT 1.5% · OPM change -0.7 pp 83% evidence 15.3/25 ROCE 6.3% · OPM 21.5% 76% evidence 10.1/20 P/E 17.2× · PEG 1.99 65% evidence 16.0/20 RS sector 6.1% · RS bench 7.1% · 1Y 11.1%12 of 12 weeks ahead 100% evidence
Exact sum: 15.5 + 15.3 + 10.1 + 16 = 56.9 · Decision use: Price leads the evidence: RS versus the benchmark is 7.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
3Newell Brands Inc.NWL 56.1/100Thin evidence · provisional58% evidence BREAKING OUT 19.5/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence 8.6/25 ROCE 3.3% · OPM 2.2% 76% evidence 9.6/20 P/E 27.8× · PEG — 15% evidence 18.4/20 RS sector 17.3% · RS bench 18% · 1Y 2.9%12 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 8.6 + 9.6 + 18.4 = 56.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Church & Dwight Co., Inc.CHD 55.4/100Mixed-positive evidence85% evidence ASLEEP 17.9/35 Revenue 2.7% · PAT 41.9% · OPM change -2.7 pp 95% evidence 17.6/25 ROCE 14.6% · OPM 18.1% 76% evidence 14.1/20 P/E 30.8× · PEG 0.66 65% evidence 5.8/20 RS sector -5.8% · RS bench -4.6% · 1Y 5.7%1 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 17.6 + 14.1 + 5.8 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Kenvue Inc.KVUE 52.5/100Mixed-positive evidence85% evidence ASLEEP 20.1/35 Revenue 1.8% · PAT 16.9% · OPM change -0.3 pp 95% evidence 14.1/25 ROCE 3.3% · OPM 17.7% 76% evidence 12.4/20 P/E 22× · PEG 1.25 65% evidence 5.9/20 RS sector -6.6% · RS bench -5.5% · 1Y -2.8%5 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 14.1 + 12.4 + 5.9 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Spectrum Brands Holdings, Inc.SPB 51.7/100Mixed-positive evidence81% evidence FADING 22.1/35 Revenue -3.7% · PAT 100% · OPM change 3.2 pp 83% evidence 8.2/25 ROCE 1.5% · OPM 6.1% 76% evidence 9.8/20 P/E 14× · PEG 2.17 65% evidence 11.6/20 RS sector 9.3% · RS bench 11.1% · 1Y 64.4%4 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 8.2 + 9.8 + 11.6 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7The Procter & Gamble CompanyPG 50.6/100Mixed-positive evidence85% evidence ASLEEP 17.2/35 Revenue 3.3% · PAT 0.5% · OPM change -2.1 pp 95% evidence 21.8/25 ROCE 24.6% · OPM 22.1% 76% evidence 6.9/20 P/E 21.7× · PEG 2.4 65% evidence 4.7/20 RS sector -8.2% · RS bench -7.3% · 1Y -5.8%0 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 21.8 + 6.9 + 4.7 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
8The Clorox CompanyCLX 49.2/100Mixed-negative evidence81% evidence ASLEEP 21.0/35 Revenue -3.7% · PAT 8.6% · OPM change 2.7 pp 83% evidence 14.6/25 ROCE 8.7% · OPM 17.3% 76% evidence 12.0/20 P/E 16.8× · PEG 1.59 65% evidence 1.6/20 RS sector -24.8% · RS bench -24.3% · 1Y -30.2%5 of 12 weeks ahead 100% evidence
Exact sum: 21 + 14.6 + 12 + 1.6 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Acme United CorporationACU 45.4/100Mixed-negative evidence75% evidence BREAKING OUT 14.1/35 Revenue 4.1% · PAT 0% · OPM change -2 pp 83% evidence 9.0/25 ROCE 1.1% · OPM 3.3% 76% evidence 5.8/20 P/E 19.4× · PEG 2.81 65% evidence 16.5/20 RS sector 27.3% · RS bench 28.7% · 1Y 42.5%9 of 12 weeks ahead 70% evidence
Exact sum: 14.1 + 9 + 5.8 + 16.5 = 45.4 · Decision use: Price leads the evidence: RS versus the benchmark is 28.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
10Magnera Corporationthis pageMAGN 43.7/100Thin evidence · provisional58% evidence ASLEEP 21.4/35 Revenue 35.3% · PAT — · OPM change 1.6 pp 62% evidence 5.7/25 ROCE 0.5% · OPM 2.1% 76% evidence 11.2/20 P/E 12.2× · PEG — 15% evidence 5.4/20 RS sector -9.9% · RS bench -9.2% · 1Y 4.3%9 of 12 weeks ahead 70% evidence
Exact sum: 21.4 + 5.7 + 11.2 + 5.4 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Colgate-Palmolive CompanyCL 42.7/100Mixed-negative evidence85% evidence ASLEEP 14.1/35 Revenue 5.2% · PAT -29.2% · OPM change -2.1 pp 95% evidence 16.6/25 ROCE 9.5% · OPM 19% 76% evidence 7.8/20 P/E 36.4× · PEG 2.2 65% evidence 4.2/20 RS sector -6.8% · RS bench -5.7% · 1Y 7.2%0 of 12 weeks ahead 100% evidence
Exact sum: 14.1 + 16.6 + 7.8 + 4.2 = 42.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Kimberly-Clark CorporationKMB 42.3/100Mixed-negative evidence85% evidence ASLEEP 16.4/35 Revenue 0.7% · PAT -20.9% · OPM change 0.9 pp 95% evidence 14.6/25 ROCE 6% · OPM 15.1% 76% evidence 7.7/20 P/E 18.7× · PEG 2.35 65% evidence 3.6/20 RS sector -13.6% · RS bench -13% · 1Y -21.3%7 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 14.6 + 7.7 + 3.6 = 42.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13The Estée Lauder Companies Inc.EL 42.2/100Mixed-negative evidence64% evidence BREAKING OUT 14.3/35 Revenue 0.3% · PAT — · OPM change -1.9 pp 62% evidence 9.4/25 ROCE 1.7% · OPM 6.7% 76% evidence 8.7/20 P/E 178× · PEG — 15% evidence 9.8/20 RS sector -4.4% · RS bench -3.8% · 1Y 8.9%6 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 9.4 + 8.7 + 9.8 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Edgewell Personal Care CompanyEPC 41.2/100Mixed-negative evidence65% evidence LEADER 8.2/35 Revenue 0.4% · PAT -139.1% · OPM change -6 pp 83% evidence 8.3/25 ROCE 0.6% · OPM 3.5% 76% evidence 9.1/20 P/E 38.4× · PEG — 15% evidence 15.6/20 RS sector 14.3% · RS bench 15.3% · 1Y 31.8%12 of 12 weeks ahead 70% evidence
Exact sum: 8.2 + 8.3 + 9.1 + 15.6 = 41.2 · Decision use: Price leads the evidence: RS versus the benchmark is 15.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15The Honest Company, Inc.HNST 39.5/100Thin evidence · provisional58% evidence LEADER 8.8/35 Revenue -9.5% · PAT — · OPM change -3.4 pp 62% evidence 4.7/25 ROCE -0.4% · OPM -0.8% 76% evidence 9.0/20 P/E 61.3× · PEG — 15% evidence 17.0/20 RS sector 46.2% · RS bench 47.7% · 1Y 36.2%10 of 12 weeks ahead 70% evidence
Exact sum: 8.8 + 4.7 + 9 + 17 = 39.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Nu Skin Enterprises, Inc.NUS 39.4/100Thin evidence · provisional58% evidence BASING 18.7/35 Revenue -14.2% · PAT — · OPM change 4 pp 62% evidence 6.2/25 ROCE 0.4% · OPM 1.3% 76% evidence 11.5/20 P/E 6.6× · PEG — 15% evidence 3.0/20 RS sector -46.1% · RS bench -46.1% · 1Y -62.1%0 of 12 weeks ahead 70% evidence
Exact sum: 18.7 + 6.2 + 11.5 + 3 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17e.l.f. Beauty, Inc.ELF 38.6/100Mixed-negative evidence81% evidence BREAKING OUT 11.3/35 Revenue 24.7% · PAT -76.8% · OPM change -24.5 pp 83% evidence 6.9/25 ROCE -3.2% · OPM -11.2% 76% evidence 3.8/20 P/E 137.8× · PEG 5.38 65% evidence 16.6/20 RS sector 5.1% · RS bench 4.5% · 1Y -33.3%12 of 12 weeks ahead 100% evidence
Exact sum: 11.3 + 6.9 + 3.8 + 16.6 = 38.6 · Decision use: Price leads the evidence: RS versus the benchmark is 4.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
18Coty Inc.COTY 30.1/100Adverse evidence64% evidence BREAKING OUT 10.1/35 Revenue -3.6% · PAT — · OPM change -7.4 pp 62% evidence 4.1/25 ROCE -4.4% · OPM -29% 76% evidence 8.5/20 P/E 20311× · PEG — 15% evidence 7.4/20 RS sector -13.1% · RS bench -13.2% · 1Y -36%10 of 12 weeks ahead 100% evidence
Exact sum: 10.1 + 4.1 + 8.5 + 7.4 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Oddity Tech Ltd.ODD 26.1/100Adverse evidence75% evidence BREAKING OUT 8.7/35 Revenue 5.1% · PAT -50.9% · OPM change -28.8 pp 83% evidence 5.4/25 ROCE -3.9% · OPM -12.9% 76% evidence 8.5/20 P/E 16.9× · PEG 2.29 65% evidence 3.5/20 RS sector -34.4% · RS bench -35.5% · 1Y -71%5 of 12 weeks ahead 70% evidence
Exact sum: 8.7 + 5.4 + 8.5 + 3.5 = 26.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Unilever PLCUL 49.3/100Thin evidence · provisional44% evidence BREAKING OUT 18.6/35 Revenue — · PAT — · OPM change — 16% evidence 13.6/25 ROCE 4.9% · OPM — 61% evidence 11.0/20 P/E 12.4× · PEG — 15% evidence 6.1/20 RS sector -9.5% · RS bench -8.9% · 1Y -9.3%5 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 13.6 + 11 + 6.1 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Magnera Corporation's stock price today?

Magnera Corporation trades at $11.6, +4.3% over the past year. The company is valued at $0.0 B. The stock sits at 46% of its 52-week range of $9–$15, −6.2% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. — as of 17 September 2026.

What were Magnera Corporation's latest quarterly results?

Magnera Corporation reported revenue of $0.8 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.50. The operating margin was 2.5%, 2.5 pp higher than a year earlier. — as of 17 September 2026.

What is Magnera Corporation's revenue?

Magnera Corporation reported revenue of $0.8 B in the Mar 26 quarter, −2.4% year on year. For the full FY25 fiscal year, revenue was $3.2 B (+46.1%). Over the last 4 years revenue compounded at 31.2% a year. — as of 17 September 2026.

What is Magnera Corporation's profit?

Magnera Corporation earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.2 B. The operating margin ran 2.5% in the latest quarter. — as of 17 September 2026.

What is Magnera Corporation's market cap?

Magnera Corporation's market capitalisation is $0.0 B at a stock price of $11.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

Does Magnera Corporation pay a dividend?

No — Magnera Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.

How is Magnera Corporation performing?

Magnera Corporation's latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

Is Magnera Corporation beating the market?

Not lately — on a trailing-13-week view Magnera Corporation is currently behind the S&P 500 (2 weeks and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.2 years the stock moved −12% against the S&P 500's +21% — behind the index over the full window. — as of 17 September 2026.

Will Magnera Corporation's stock price go up?

This page publishes no price forecast for Magnera Corporation. What it measures instead: the stock price is $11.6. Direction is not something this site claims to know. — as of 17 September 2026.

Is the market betting against Magnera Corporation?

Somewhat — short interest is 6.5% of Magnera Corporation's tradable float, about 4.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does Magnera Corporation have too much debt?

It carries real leverage — Magnera Corporation's debt-to-equity is 1.93. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.

What is Magnera Corporation's capex?

Magnera Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 17 September 2026.

What is Magnera Corporation's cash flow?

Magnera Corporation generated $0.1 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $−0.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.

Is Magnera Corporation's profit real cash?

Yes — over the last 2 fiscal years, 660% of Magnera Corporation's reported profit arrived as operating cash. Though the latest year ran at -62% — the trend is the thing to watch. In FY25, operating cash was $0.1 B against reported profit of $−0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.

How financially safe is Magnera Corporation?

On the balance sheet, the Z-score reads 1.24 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 17 September 2026.

Where is Magnera Corporation in its business cycle?

Magnera Corporation's FY25 operating margin was 0.3%, against a 5-year band of −10.7%–3.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 2.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Magnera Corporation story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Magnera Corporation a stock worth studying right now?

This is not investment advice. The machine read: Magnera Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI